DaShenLin Pharmaceutical Group Co

DaShenLin Pharmaceutical Group Co Intangible Assets

The Intangible Assets of DaShenLin Pharmaceutical Group Co (603233.SS) as of Oct 30, 2026 is 1.99 B CNY. In the previous year, Intangible Assets was 1.88 B CNY — a change of 5.92% (higher).

Intangible Assets

1.99 BCNY

YoY

5.92%

Last updated:

Intangible Assets of DaShenLin Pharmaceutical Group Co is 2024 1.99 B CNY. Intangible Assets of DaShenLin Pharmaceutical Group Co was 2023 1.88 B CNY. It decreases by 5.92% higher compared to the previous year.

The DaShenLin Pharmaceutical Group Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
114.00 M CNY
Jan 1, 2018
288.00 M CNY
Jan 1, 2019
385.00 M CNY
Jan 1, 2020
539.00 M CNY
Jan 1, 2021
676.41 M CNY
Jan 1, 2022
700.55 M CNY
Jan 1, 2023
1.88 B CNY
Jan 1, 2024
1.99 B CNY
The DaShenLin Pharmaceutical Group Co Intangible Assets history
YEARIntangible AssetsYoY
1.99 BCNY+5.92%
1.88 BCNY+168.36%
700.55 MCNY+3.57%
676.41 MCNY+25.49%
539.00 MCNY+40.00%
385.00 MCNY+33.68%
288.00 MCNY+152.63%
114.00 MCNY+70.15%
67.00 MCNY+4.69%
64.00 MCNY+28.00%
50.00 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DaShenLin Pharmaceutical Group Co Stock analysis

What does DaShenLin Pharmaceutical Group Co do? DaShenLin Pharmaceutical Group Co Ltd generates revenue through the retail and wholesale of pharmaceutical products, including Chinese and Western medicine, ginseng nourishing herbs, Chinese medicine pieces, health products, and medical apparatus. The company operates primarily within the domestic market, serving customers who purchase these healthcare commodities directly or through its retail channels. Its business model relies on direct sales and retailing as key revenue streams, targeting consumers and businesses seeking pharmaceutical and health-related products. The firm's product portfolio encompasses a wide range of healthcare items, from traditional Chinese medicine to modern medical devices, all sold under its own brand within China's domestic market. With a focus on both direct sales and retail distribution, DaShenLin Pharmaceutical Group Co Ltd caters to a diverse customer base that includes individual consumers and healthcare institutions requiring medical supplies and health products. DaShenLin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DaShenLin Pharmaceutical Group Co stock

Intangible Assets of DaShenLin Pharmaceutical Group Co is 1.99 B CNY in 2024.

Intangible Assets of DaShenLin Pharmaceutical Group Co changed from 1.88 B CNY to 1.99 B CNY, representing a 5.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets DaShenLin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's DaShenLin Pharmaceutical Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — DaShenLin Pharmaceutical Group Co

All Key Metrics — DaShenLin Pharmaceutical Group Co